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Introduction
Fever is a nonspeciﬁ  c response to various types of infec-
tious or non-infectious stimuli. Th  e incidence in ICUs 
ranges from 23 to 70% and is related to an infectious 
process in only one-half of the cases [1-3]. In the past two 
decades, numerous studies have underlined the deleter-
ious eﬀ  ects of fever on outcome, especially in neuro-
logical diseases, leading to active treatment of fever with 
medications and/or various physical means [4]. However, 
the rationale for extending such a strategy to septic 
patients is not supported by clinical data, and several 
lines of evidence suggest that fever in these patients may 
be helpful to ﬁ  ght the infectious process. Some practices, 
such as fever-induced discomfort and/or favoured febrile 
seizures, have been reconsidered [5-8]. Moreover, fever is 
a cornerstone diagnostic sign in clinical practice that 
helps to start early appropriate therapy and to follow the 
infection course. Besides, sepsis biomarkers (that is, pro-
calci  tonin, C-reactive protein) have to prove their rele-
vance [9]. Finally, antipyretic therapies have side eﬀ  ects 
that must be taken into account when physicians decide 
to control fever.
Th   e objective of the present review is to delineate the 
advantages and drawbacks of fever in septic patients. Th  e 
main side eﬀ   ects of antipyretic therapies are also 
emphasised.
Defi  nition and pathophysiology of fever
Th   e core body temperature is tightly regulated around a 
set point by homeostatic mechanisms under normal 
physiological conditions. Nevertheless, there is a female 
hormonal-induced variation and a diurnal variation. So, 
Mackowiak and colleagues found that the mean tempera-
ture was 36.8°C, with a range of 35.6 to 38.2°C, the 
temperature being lower in the morning than in the 
evening [1].
Fever is an upregulation of the hypothalamic tempera-
ture and is often diﬃ   cult  to  diﬀ  erentiate from hyper-
thermic syndromes. In the latter, the setpoint remains 
unchanged but involves a dysregulation of peripheral 
mechanisms of heat production or loss. Th  e threshold 
value of fever diﬀ   ers between epidemiological ICU 
studies, ranging from 38.3 to 38.5°C [2,10,11], but a 
threshold value of ≥38.3°C has been recommended by 
several societies for the diagnosis of fever [12,13]. Th  is 
deﬁ   nition has to be considered with regards to the 
methods used to determine the temperature. Indeed, the 
core temperature is important as a core to peripheral 
temperature gradient is common in critically ill patients, 
especially in those who are hypovolaemic, have a low 
cardiac output or are peripherally vasoconstricted. In the 
ICU, the temperature reference is provided by the 
thermistance of the pulmonary artery catheter, but most 
of the patients have no such device in place. In addition, 
comparison with other methods of temperature measure-
ment is far from being well corre  lated. Accordingly, it has 
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measurement that better accuracy was obtained for the 
urinary or oesophageal temperature [14,15].
Fever is a preserved phylogenetic response to a wide 
variety of infectious and non-infectious triggers, which 
induce, by diﬀ   erent methods, upregulation of the 
thermo  static setpoint in the preoptic area of the 
hypothalamus, ﬁ  nally resulting in fever. Several methods 
of activation of the hypothalamus have been described 
(Figure 1). Classically, the pathogen-associated molecular 
patterns (called exogenous pyrogens) stimulate leuko-
cytes, which in turn produce cytokines (called endoge-
nous pyrogens), mainly IL-1β, TNFα and IL-6 [16]. Th  ese 
endogenous pyrogens activate the febrile res  ponse 
indirectly, by inducing secretion of prostaglandin E2 in 
the organum vasculosum of the lamina propria located 
just below the preoptic area of the hypothalamus. Two 
other methods are recognised. Th  e ﬁ   rst, recently des-
cribed, is also mediated by IL-1β but involves ceramide 
production by an enzymatic pathway (neutral sphingo-
myelinase) [17]. Ceramide therefore acts as a second 
messenger in place of prostaglandin E2, which explains 
the early rise in core temperature [17]. Th  e remaining 
method is neuronal and independent of cyto  kine pro  duc-
tion. Th   e Küppfer cells stimulated by lipopoly  saccharide 
produce prostaglandin E2, which in turn elicits a 
hypothalamic response through a neural pathway 
mediated by the vagus nerve and the nucleus tractus 
solitarius [18,19]. Th  ese pathophysiological considera-
tions explain why fever may be induced by inﬂ  ammation 
or infection.
Benefi  cial eff  ects of fever
While many years of clinical observations and several 
published observational studies suggest fever is beneﬁ  cial 
to the host, it is important to emphasise the lack of robust 
clinical evidence concerning the assessment of fever’s 
beneﬁ   ts. How fever could inﬂ   uence outcome in septic 
patients is a key issue that remains debated because of the 
limited value of studies that included a heterogeneous 
population of patients with diﬀ  erent levels of severity of 
sepsis. Nevertheless, a set of arguments can help en  lighten 
this issue. Indeed, there are direct arguments that refer to 
the beneﬁ  cial eﬀ  ects of fever per se and indirect arguments 
that reﬂ  ect the noxious eﬀ  ects of fever suppression.
Direct arguments
Fever eff  ects on infectious agents
Fever has an impact on microorganism growth. Human 
pathogen infectious agents usually grow under optimal 
Figure 1. Proposed methods of activation of the hypothalamus. LPS, lipopolysaccharide; PAMP, pathogen-associated molecular pattern; PGE2, 
prostaglandin E2.
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Page 2 of 7temperatures of around 35 to 37°C [20]. In experimental 
meningitis, the elevated body temperature increases the 
pneumococci growth time in cerebral spinal ﬂ  uid when 
compared with a blunted febrile response induced by 
urethane [21]. Similarly, an in vitro study on Plasmodium 
falciparum concluded that febrile temperatures play a 
role in inhibiting parasite growth [22]. Experimentally, 
increas  ing the temperature from 35 to 41.5°C on 432 
strains of bacteria revealed a progressive rise in the 
activity of antimicrobial agents (17 antimicrobial agents 
tested) and a reduction in the minimum inhibitory 
concen trations  [23].
Eff  ects of fever on immunity and heat shock response
Fever is also known to modulate the cellular immune 
response and to induce the heat shock response. Hyper-
thermic preconditioning of a rat model of peritonitis 
reduced the severity of infection, prevented a decrease in 
the number of CD4 lymphocytes and B cells, and 
decreased the serum level of the proinﬂ  ammatory 
cytokine TNFα [24]. Furthermore, other studies reported 
an increase in the mobility of polymorphonuclear cells, in 
the phagocytosis speed, in lymphocyte recruitment, in 
adherence of T-helper lymphocytes to L-selectin, in 
immunoglobulin levels and in TNFα cytotoxicity in 
response to elevated temperature [25].
Heat shock proteins are critical for cellular protection 
in reducing endothelial and organ damage during several 
stresses including fever. Recent data demonstrated that a 
heat shock response can downregulate the activity of 
NF-κB, modulating the immune response [26]. Reduced 
mortality and organ injury were reported after heat 
pretreatment in a rat model of intra-abdominal sepsis 
and sepsis-induced lung injury, with increased levels of 
HSP-72 in the lungs and heart of the heat-treated animals 
[27]. More recently, in a sheep model of peritonitis, 
febrile animals had a longer survival time with 
concomitant higher HSP-70 levels when compared with 
the other animals [28].
Clinical data
Direct clinical evidence is supported by old studies and 
more recent studies. A retrospective analysis of 218 
patients with Gram-negative bacilli bacteraemia reported 
signiﬁ  cantly higher survival in patients who developed 
fever on the day of bacteraemia [29]. Th  e mortality of 
patients with spontaneous bacterial peritonitis was 
reduced when the body temperature was >38°C [30]. In 
the same disease, a positive correlation between body 
temperature increase and survival has been shown [31]. 
In elderly patients with community-acquired pneumonia, 
a higher mortality rate was observed in patients who 
lacked fever when compared with patients who developed 
a febrile response (29% vs. 4%) [32]. More recently, the 
multicenter French AmarCand study pointed out that 
fever >38.2°C was a protective factor in invasive Candida 
spp. infections in the ICU [33]. In a selected population 
of ICU-infected patients, both hypothermia and fever 
increased morbidity and mortality rates, but patients 
with hypothermia had a higher mortality when compared 
with those who had fever (80% vs. 47%) [11]. In a similar 
selected population, Arons and colleagues reported an 
increased mortality in hypothermic patients. Interest-
ingly, the inﬂ  amma  tory response was increased in these 
patients when compared with febrile patients, suggesting 
a protective eﬀ  ect of fever per se [34].
Indirect arguments
Experimental data
Beneﬁ  cial eﬀ  ects of fever are reported in several experi-
mental studies. Ectothermic desert lizards (Dipsosaurus 
dorsalis) infected by Aeromonas hydrophilia had a 
greater survival rate when they were placed in a warm 
environment [35]. Subsequently, in the same model, the 
suppression of fever by an injection of sodium salicylate 
was demonstrated to dramatically increase mortality 
[36]. Similarly, in a murine bacterial peritonitis model, 
increasing the core temperature by housing mice in a 
35.5°C ambient temperature led to an improved survival 
rate when compared with animals placed in a cooler 
environment. Moreover, TNFα expression was sup-
pressed in the early 48 hours and IFNγ expression was 
delayed. Interestingly, after animal sacriﬁ  ce, signiﬁ  cantly 
lower concentrations of bacteria per organ were observed 
in animals with fever when compared with cooled 
animals [37].
Su and colleagues explored the eﬀ  ects of controlling 
fever with paracetamol or external cooling in a sheep 
septic shock model. Th  e febrile animals had better 
respiratory function and a prolonged survival time [28]. 
Finally, a recent meta-analysis that included eight studies 
on inﬂ  uenza-infected animals reported an increased risk 
of mortality when the animals received various anti-
pyretic treatments (odds ratio = 1.34, 95% conﬁ  dence 
interval = 1.04 to 1.73) [38].
Clinical data
Several clinical studies indirectly advocate a beneﬁ  cial 
eﬀ  ect of fever. For instance, in a placebo-controlled trial, 
Graham and colleagues compared the eﬀ  ects of aspirin 
and paracetamol on virus shedding, immune response 
and clinical status in rhinovirus-infected volunteers. In 
the aspirin and paracetamol group, a longer duration of 
virus shedding and suppression of serum-neutralising 
antibody response were observed [5]. In addition, 
another randomised trial showed that treatment of fever 
with paracetamol in P. falciparum malaria-infected 
children prolonged the parasite clearance time when 
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study demonstrated that prophylactic adminis  tration of 
antipyretic drugs at the time of vaccination induced a 
delayed and lower antibody response to several vaccine 
antigens, although paracetamol similarly aﬀ  ected 
antibody response in children with or without fever [40]. 
Finally, a randomised study in febrile surgical and trauma 
critically ill patients to assess the impact of antipyretic 
therapy on infection development was interrupted after 
the ﬁ  rst interim analysis, because of higher mortality in 
the antipyretic group (seven deaths vs. one death, 
P  =  0.06). Moreover, the infection rate tended to be 
higher in the treated group (4 ± 6 per patient vs. 3 ± 2 per 
patient, P = 0.26) [41].
Th   ese indirect data reinforce the concept that fever may 
play a role in the survival of septic patients, although the 
impact of antipyretics on morbidity cannot be excluded.
Detrimental eff  ects of fever
Even though the febrile response seems useful in the 
adaptive reaction to a stressful situation, it could cause 
several detrimental eﬀ  ects on clinical outcomes. Indeed, 
fever increases metabolic demand and consequently 
oxygen consumption of diﬀ   erent organs, notably the 
brain and the heart, and worsens pre-existing disease. For 
instance, in neurological injuries, fever is now a well-
recognised factor of secondary cerebral insult and 
contributes to deterioration of the clinical outcome [4]. 
In acute ischaemic stroke, studies suggest that fever is 
strongly associated with signiﬁ   cant morbidity and a 
mortality increase up to 20% [42,43]. A similar issue is 
raised in traumatic brain injuries in which fever is 
responsible for overwhelming secondary brain injuries 
[44]. In neurological injuries, therefore, the control of 
fever is a major therapeutic axis to prevent worsening of 
the primary lesions, despite the lack of prospective 
studies that assess the impact of a normothermia strategy 
on the outcome [45].
Myocardial injuries are another disease category in 
which fever can be deleterious. Because of increased 
oxygen consumption, patients with underlying heart 
diseases, especially coronary disease and ischaemic 
cardio  myopathy, are more exposed to the systemic eﬀ  ects 
of fever. In a swine model of acute myocardial infarction, 
an elevation of body temperature up to 39°C provoked an 
increased infarct size [46]. Similarly, in febrile critically ill 
patients, the reduction of fever from 39 to 37°C induced a 
decrease of oxygen consumption and unloaded the 
cardiorespiratory system, which favoured resuscitation of 
patients who had limited oxygen delivery [47]. In these 
situations, the beneﬁ   ts of fever control when an 
infectious process is ongoing must be counterbalanced 
by the inherent beneﬁ  ts of fever. However, no clinical 
data are available to support such an approach.
Th   e discomfort from fever is usually claimed to justify 
fever treatment, although it is not clear whether the dis-
comfort is due to fever per se or rather to the neuro-
endocrine and/or metabolic response to an infectious 
process [8,48]. Similarly, the preventive treatment of 
fever to avoid febrile seizures in children remains a 
largely debated and controversial issue [6].
Finally, it has been hypothesised that fever could induce 
collateral tissue damage as a consequence of enhanced 
microbial killing mechanisms. In a mouse model of 
Gram-negative bacterial pneumonia, fever tended to 
worsen survival despite enhanced innate host defence 
and successful elimination of pathogens. Th  e authors 
found that the reduced survival was accompanied by 
increased vascular pulmonary injury, enhanced accumu-
lation of neutrophils and increased levels of cytokines in 
the bronchoalveolar lavage [49]. Indeed, the same process 
could also initiate injury to host tissues, suggesting the 
fact that the ultimate eﬀ  ect of fever is determined by the 
balance between accelerated pathogen clearance and 
collateral tissue injury. At a high fever level (>40 to 41°C), 
however, the beneﬁ  cial immunomodulatory eﬀ  ect could 
be outweighed by the deleterious metabolic/inﬂ  amma-
tory eﬀ  ect of fever.
Side eff  ects of antipyretic treatments
Despite a lack of experimental and clinical data, febrile 
ICU patients are frequently treated to lower their fever 
response [50]. Methods of treatment include direct 
cooling and/or antipyretic medications such as non-
steroidal anti-inﬂ  ammatory drugs (NSAIDs) and parace-
tamol. Th  ese treatments may delay early diagnosis and 
appropriate therapy of major infections, and they carry 
their own undesirable side eﬀ  ects (bleeding, hypotension, 
hepatic and renal toxicity). Th   ese consequences must be 
taken into account when fever-reducing therapy is 
initiated in critically ill patients.
Paracetamol
Th   e most serious adverse eﬀ  ect of paracetamol is a life-
threatening hepatic necrosis related to overdosage. Th  is 
necrosis leads to hepatocellular injury in relation to the 
toxic N-acetyl-p-benzo-quinone imine metabolite when 
the capacity of glutathione is exceeded. In normal use, 
paracetamol is safe – but it is noteworthy that acute 
hepatitis may occur in ICU patients who have reduced 
glutathione reserves, such as in alcoholics and/or mal-
nourished patients [51]. In addition, clinical evidence 
suggests that the same metabolic pathway could be 
involved in the kidney and plays a role in analgesic-
associated nephropathy [52].
Interestingly, in a randomised single-blind study, 
healthy volunteers who received paracetamol (4 g daily 
for 14 days) experienced a signiﬁ  cant increase of serum 
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[53]. Th  e incidence of maximum alanine aminotrans-
ferase increased more than three times the upper normal 
value in approximately one-third of treated patients. Th  e 
clinical signiﬁ   cance of the alanine aminotransferase 
elevation is unclear but the implication in ICU patients 
warrants further investigation.
In contrast to NSAIDs, paracetamol usually is not 
considered to inﬂ  uence platelet function. However, intra-
venous paracetamol has been shown to inhibit platelet 
cyclooxygenase-1 in a dose-dependent anti-aggregatory 
manner in healthy volunteers [54].
Finally, the potential for paracetamol to produce 
cardio  vascular toxicity is low. Blood pressure was 
signiﬁ  cantly reduced, however, after administration of 1 g 
paracetamol by mouth or feeding tube [55]. More recently, 
in 14 febrile critically ill patients, Hersch and colleagues 
administered an intravenous bolus of propacetamol, 2 g 
over 15 to 20 minutes, and showed that blood pressure 
was signiﬁ   cantly decreased 15  minutes after infusion. 
Noteworthy, the systolic blood pressure dropped to 
<90  mmHg in approximately one-third of patients, 
requiring both ﬂ  uid administration and norepinephrine 
escalade or infusion [56].
Nonsteroidal anti-infl  ammatory drugs
Th  e main side eﬀ  ect of NSAIDs, gastrointestinal bleed-
ing, derives from their capacity to inhibit cyclooxygenase. 
NSAIDs with a high aﬃ   nity for cyclooxygenase-1 are 10 
times more likely to induce a gastrointestinal event such 
as mucosal lesions, a perforated ulcer or gastrointestinal 
bleeding [57]. NSAIDs are also known to have adverse 
eﬀ  ects on kidney function through inhibition of prosta-
glandin synthesis, notably when used in situations in 
which the renin–angiotensin system is stimulated, such 
as volume depletion, pre-existing renal failure or con-
comitant nephrotoxic agents [58,59]. Of note, some 
NSAIDs may cause vasospasm in patients who have 
previous coronary artery disease [60].
Risk factors for severe NSAID-induced adverse eﬀ  ects 
include high dosage, advanced age, concomitant use of 
steroids or anticoagulants and short duration of therapy, 
situations that are frequently observed in ICU patients 
[61].
Physical methods
Physical cooling is usually indicated for the treatment of 
hyperthermia and fever, but its use remains controversial 
because of the propensity to induce sympathetic activa-
tion, cutaneous vasoconstriction and shivering [62]. As a 
ﬁ   rst consequence, in febrile patients the capacity of 
external cooling to lower the core temperature may be 
limited by thermoregulatory mechanisms aiming to 
maintain the elevated body temperature [63]. Second, if 
shivering is present, physical cooling causes a rise in 
oxygen consumption and may be deleterious. In volun-
teers, induction of fever and active external cooling 
increased oxygen consumption up to 40% and was asso-
ciated with a signiﬁ  cant increase in catecholamine levels 
[62]. Th   erefore, when external cooling is used in the ICU, 
it is frequently necessary to inhibit shivering by adminis-
tering therapeutic myorelaxant medication [47]. Moreover, 
the use of a hypothermia blanket in febrile ICU patients 
has been shown to induce a large temperature ﬂ  uctuation 
and frequent rebound hypothermia [64].
Extracorporeal mechanisms
Although techniques such as extracorporeal membrane 
oxygenation, haemodialysis or plasmapheresis are not 
speciﬁ  cally used to decrease fever, they generally lead to 
Table 1. Summary of the benefi  cial and detrimental eff  ects of fever
Benefi  cial eff  ects Detrimental eff  ects
On invading microorganism
    Reduced growth/prolonged growth time
    Increased antibiotic sensitivity/reduced minimal inhibitory concentration
Accelerated immune response
    Increased mobility of polymorphonuclear cells
    Increased phagocytosis
    Increased T-helper cell adherence
    Prevention of lymphocytes cell reduction (CD4 T cells and B cells)
Attenuated immune response/protection against the collateral damage
    Increased heat shock protein causing a decrease of NF-κB 
    Reduced TNFα
    Reduced IFNγ
Increased metabolic demand and oxygen consumption (myocardial and 
neurological injuries)
Source of patients’ discomfort?
Children’s seizures? (Controversial)
Collateral tissue damage?
Launey et al. Critical Care 2011, 15:222 
http://ccforum.com/content/15/3/222
Page 5 of 7normothermia in febrile patients. However, the impact of 
such consequences remains elusive.
Conclusion
In light of these concerns, healthcare providers have to 
consider carefully whether to use an antipyretic tech-
nique and/or agent in ICU patients by weighing up the 
risks and the possible beneﬁ  ts.
Conclusion
Fever is a basic response triggered by an infectious or a 
non-infectious process. Th   e balance of beneﬁ  t to harm of 
fever in septic ICU patients is complex. Th  is balance is 
likely to be dependent on the stage and severity of the 
infection, on the intensity of the immune response, on 
the extent of systemic inﬂ  ammatory  response-induced 
collateral tissue damage as well as on the underlying 
physiological reserve of the patient (Table 1). On the 
other hand, the widespread use of antipyretic methods in 
ICU patients is not supported by clinical data and fever 
control may be harmful, particularly when an infectious 
disease is progressing. We await appropriately designed, 
prospec  tive randomised trials to deﬁ  ne patient groups 
likely to beneﬁ  t from or be harmed by antipyretic treat-
ment. Th  e decision to introduce an antipyretic therapy 
should be well balanced according to the presence of 
neurological injuries and/or underlying cardiac disease 
and the absence of sepsis.
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